אסטרוגנוס ® 0.3 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.3 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:1. treatment of moderate to severe vasomotor symptoms associated with menopause. 2. treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.
אסטרוגנוס ® 0.45 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.45 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 0.625 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.625 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 0.9 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.9 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 1.25 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 1.25 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
דואביב
pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - טבליות בשחרור מושהה - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
אקטיבל
novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
מירנה
bayer israel ltd - levonorgestrel - התקן תוך רחמי - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.
נויטרוג'ינה - קרם לחות נטול שומן לעור מעורב
ג'יי-סי הלת'קר בעמ - לחות לפנים